Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the digestive tract, and this disease has served as a paradigmatic model for successful rational development of targeted therapies. The introduction of tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized and advanced stages has remarkably improved the survival in a disease formerly deemed resistant to all systemic therapies. The Spanish Society of Medical Oncology (SEOM) guidelines provide a multidisciplinary and updated consensus for the diagnosis and treatment of GIST patients. We strongly encourage that the managing of these patients should be performed within multidisciplinary teams in reference centers.
Poveda, A., Martinez, V., Serrano, C., Sevilla, I., Lecumberri, M. J., de Beveridge, R. D., … Martin-Broto, J. (2016). SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016). Clinical and Translational Oncology, 18(12), 1221–1228. https://doi.org/10.1007/s12094-016-1579-9